Recently, a novel recurrent translocation t(3;14)(p14.1;q32) was reported that results in the deregulated expression of the Forkhead Box P1 (FOXP1) gene by juxtaposing it to the immunoglobulin (Ig) H regulatory elements. 1 In particular, Streubel et al. 1 identified nine cases of low-grade marginal zone B-cell lymphomas (MZBL) of different localizations harboring this translocation. These results suggest that FOXP1 translocations may represent a novel recurrent genetic aberration in extranodal low-grade MZBL, besides the known t(11;18), t(14;18) and t (1;14) . In two subsequent studies, FOXP1 translocations were also identified in two cases of diffuse large B-cell lymphoma (DLBCL) suggesting that this genetic event may not be confined to MZBL alone. 2, 3 Here, we report on genetic alterations of the FOXP1 locus and FOXP1 protein expression in a large series of B-cell lymphomas. In total, 275 B-cell non-Hodgkin's lymphomas (B-NHL), referred to the Institute of Pathology, University of Wü rzburg, were included in this study (102 DLBCL, of which 49 were primary nodal and 53 extranodal tumors, 122 extranodal MZBL of MALT type from different localizations (nine cutaneous, 13 salivary gland, 50 pulmonary, 36 ocular adnexa, eight thyroid gland and six gastric tumors), 30 follicular lymphomas (FL) and 21 mantle cell lymphomas (MCL)). All samples were submitted to a standard immunostaining procedure and classified according to the World Health Organization (WHO) criteria. 4 Chromosomal breakpoints and copy number changes of the FOXP1 locus were studied by fluorescence in situ hybridization (FISH) on tissue microarrays and routine paraffin sections. The genomic clones that both cover and flank the FOXP1 locus were selected according to their location, using Map Viewer at www.ncbi.nih.gov and www.ensembl.org and designed for segregation and colocalization interphase FISH assay ( Figure 1a ). In total, five out of 275 B-cell lymphomas were found to carry a chromosomal breakpoint in the FOXP1 locus, based on the presence of segregated, single FISH signals when hybridized with the FOXP1 flanking probes (Table 1 ). All samples that harbored a breakpoint in the FOXP1 locus represented DLBCL with a proliferative index of 70-90%, as defined by Ki67 labeling (Table 1, Figure 1b and c). Interestingly, four out of five tumors presented at extranodal sites: three in the gastro-intestinal tract and one in the thyroid gland. In contrast, not a single case of 122 extranodal MZBL carried a breakpoint in the FOXP1 locus. This finding is surprising and in contrast to the original report. 1 It is unlikely that differences in technical procedures account for this discrepancy, as the FISH assays in both studies use DNA probes flanking comparable genomic regions in the FOXP1 locus. Whereas Streubel et al. Letters to the Editor was found to carry a breakpoint involving the MALT1 locus. Therefore, this approach may have enriched for MZBL cases with FOXP1 translocations, as apparently breakpoints at the FOXP1 and MALT1 loci are mutually exclusive.
Although the overall frequency of the FOXP1 translocation appears to be relatively low among B-NHL (2%), the interesting finding in our series is the exclusive occurrence in DLBCL and its strong association with extranodal presentation. It should be noted that no low-grade component was observed in any of the five DLBCL. In addition, none of the five patients had records of a prior low-grade lymphoma. The morphological spectrum of the cases included centroblastic and anaplastic DLBCL variants. Interestingly, none of the five DLBCL showed expression of the germinal center marker CD10, although using the immunohistochemical criteria of Hans et al.,
5 three cases would have been assigned to the germinal center B-cell like-DLBCL subgroup based on the strong expression of BCL-6 alone. In keeping with our data, one case of gastric DLBCL with a FOXP1/IgH translocation, recently reported by Fenton et al., 3 had the same immunophenotype. In addition, three of the cases in our series that carried a chromosomal breakpoint in FOXP1 were also localized in the stomach, indicating that FOXP1 rearrangements may be more frequent in gastric DLBCL. These cases may have been missed by Streubel et al.
1 who failed to identify FOXP1 translocations in their gastric cases because they excluded aggressive lymphomas from their study.
Fluorescence in situ hybridization analysis in cases 1 and 2 revealed a loss of one of the FOXP1 flanking probes (one loss telomeric and one loss centromeric of the FOXP1 locus, respectively), suggesting loss of genomic material in this region (Figure 1d ). Cytogenetic analysis revealed complex karyotypes with more than three structural abnormalities in cases 1 and 3 (Table 1) . Altogether cytogenetic and FISH data of our cases indicated that FOXP1 rearrangements are associated with complex karyotypes. Case 4 showed evidence for trisomy 3 both on banding analysis and FISH, and the FISH breakpoint assay for the FOXP1 locus indicated a chromosomal breakpoint involving the one FOXP1 locus and two intact FOXP1 loci. Interestingly, this signal constellation was only detected in 60% of the cells with trisomy 3, whereas the remaining cells had three pairs of colocalizing signals representing three intact FOXP1 loci. These data indicate that the chromosomal break in the FOXP1 locus was present only in a subset of tumor cells, suggesting that the FOXP1 rearrangement represents a secondary or late event in lymphomagenesis.
Only cases 1 and 5 (Table 1 ) of all five rearranged cases showed evidence of a FOXP1/IgH translocation, indicated by the colocalization of FISH probes mapping to the FOXP1 gene and IgH locus. No FOXP1/IgH probe colocalization was detected in the remaining three samples, pointing to the possible involvement of an alternative translocation partner. Further FISH analysis with IgK and IgL DNA Split Signal probes (Dako Deutschland GmbH, Hamburg, Deutschland, Denmark) identified no chromosomal breakpoints involving k and l Ig loci. A juxtaposition of FOXP1 to small Ig fragments containing enhancer elements, however, may be undetectable by FISH and, therefore, cannot be ruled out completely. Interestingly, a breakpoint in the IgH locus was further identified by the segregation of the IgH break apart probes (Abbott GmbH & Company KG, Wiesbaden-Delkenheim, Germany) in cases 1, 3 and 5. In keeping with this finding, the available karyotype in case 3 indicated the presence of an 14q32/IgH breakpoint in addition to a t(3;10)(p21;p13), suggesting sequences in the chromosomal region 10p13 as a FOXP1 translocation partner in this sample. This finding is in agreement with the recent report 68B89/4nS,XXYY,+der(X),À2,t(3;10)(p21;p13),der(10) t(3;10)(p21;p13),der(13)t(13;14)(q33;q13)x2,der (14) Letters to the Editor from Wlodarska et al., 2 who proposed a non-IgH FOXP1 translocation partner on chromosome 2q36 in one lymphoma, based on available cytogenetic data. Therefore, FOXP1 may exhibit a similar promiscuity with respect to its translocation partners, as has been reported for other genes (e.g. BCL6) that are frequently involved in translocations in B-cell lymphomas. In three cases (N2, 3 and 5) the FOXP1 breakpoints we mapped by interphase FISH to the 5 0 end of the FOXP1 gene as previously reported by Streubel et al.
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Recent studies have identified a variable percentage of DLBCL with strong nuclear expression of the FOXP1 protein and, at least in some series, FOXP1 expression appears to be associated with poor survival among DLBCL patients. [5] [6] [7] However, molecular mechanisms that are involved in the regulation of FOXP1 expression are largely unknown. A gain of genomic material suggested by the presence of additional FISH signals (three or four) at the FOXP1 locus was found in 79 samples (29%) included in this study (30 DLBCL, 45 MZBL, three FL and one MCL, respectively; Figure 1f ). The percentages of cells carrying a gain varied from 10 to 95% in different samples. Using classical cytogenetic data and subsequent FISH analysis with a chromosome 3, a-satellite peri-centrometic probe (Abbott), we were able to further clarify this abnormality in 32 samples. Our data indicated the presence of trisomy 3 in the majority (75%) of samples with over-representation of the FOXP1 locus.
All evaluable samples (four of five) that harbored a chromosomal breakpoint in the FOXP1 locus showed strong nuclear FOXP1 protein expression patterns when stained with the JC12 monoclonal antibody (Figure 1e ). In addition, FOXP1 protein expression was evaluated in representative samples with and without over-representation of the FOXP1 locus. Nuclear expression in a varying proportion of the cells was detected in 38 out of 40 cases (95%) with a genomic gain/trisomy 3 ( Figure 1g ). However, FOXP1 protein expression was also observed in 19 out of 48 samples (40%) without evidence of genetic imbalances at this locus. Our results, together with published data 1, 2 indicate that genetic alterations at the 3p13 locus, which include chromosomal breakpoints or more frequently, genomic gains of the FOXP1 locus or trisomy 3, are associated with strong FOXP1 protein expression. Interestingly, a recent study of Bea et al. 8 reported genomic gains of chromosome 3 to be associated with the activated B-cell (ABC)-like DLBCL subtype and, therefore, as an adverse prognostic factor in DLBCL. It has to be noted, however, that a proportion of DLBCL without evidence of genetic aberrations of the FOXP1 locus or trisomy 3 shows similarly strong FOXP1 protein expression levels suggesting that mechanisms other than underlying genetic alterations can upregulate FOXP1 protein expression (e.g. as part of a physiological response of FOXP1 upon B-cell activation or by epigenetic mechanisms). Asparagine synthetase (ASY) is an enzyme that produces asparagine from aspartic acid in an ATP-dependent manner.
The ASY gene is conserved in mammalian cells; however, the expression of the gene is repressed in acute lymphoblastic leukemia (ALL) cells preventing them from synthesizing asparagine. 1 As ALL cells depend on extracellular sources of asparagine to survive, depletion of asparagine by L-asparaginase leads to cell death; therefore, the enzyme has been used for the
